Table 6.

Summary of previous results of SVZ irradiation and main results from the current study

Studies	n =	Cut-off mean dose to SVZ	TTP (months) HR (IC95%)	p	OS (months) HR (IC95%)	p
Evers 2010 [34]	55	bSVZ ≥ 43Gy vs < 43Gy	15 vs 7.2	0.028*	NK	NA
		bSVZ dose (continuous) ma	0.73 (0.57–0.95)	0.019*	NK	NA
Slotman 2011 [35]	40	bSVZ ≥ 43Gy vs < 43Gy	13.2 vs 13.1	0.740	18.6 vs 20.1	0.930
Lee 2012 [36]	173	iSVZ > 59.4Gy vs ≤ 59.4Gy	12.6 vs 9.9	0.042*	25.8 vs 19.2	0.173
		iSVZ > 59.4Gy ma	0.45 (0.25–0.82)	0.009*	0.65 (0.35–1.21)	0.177
Gupta 2012 [37]	40	iSVZ > 59.9Gy vs ≤ 59.9Gy	10 vs 11	0.920	17 vs 15	0.950
		iSVZ dose (continuous) ma	0.91 (0.80–1.03)	0.116	0.87 (0.77–0.98)	0.025*
		cSVZ > 57.9Gy vs ≤ 57.9Gy	NR vs 10	0.02*	NR vs 14	0.05
		cSVZ > 57.9Gy ma	0.96 (0.91–1.30)	0.797	0.95 (0.72–1.26)	0.736
Chen 2013 [38]	116	iSVZ ≥ 40Gy vs < 40Gy	0.82 (0.51–1.34)	0.434	0.93 (0.57–1.50)	0.754
		GTR subgroup:
		iSVZ ≥ 40Gy vs < 40Gy	15.1 vs 10.3	0.023 *	17.5 vs 15.6	0.027 *
		iSVZ ≥ 40Gy ma	0.39 (0.17–0.90)	0.028 *	0.39 (0.17–0.90)	0.027 *
Elicin 2014 [39]	60	cSVZ ≥ 59.2Gy vs < 59.2Gy	7.1 vs 10.4	0.009*	NK	NA
		cSVZ ≥ 59.2Gy ma	1.72 (0.80–3.53)	0.161
Adeberg 2016 [40]	54	iSVZ ≥ 40Gy vs < 40Gy	8.5 vs 5.2	0.013*	21.3 vs 18.0	0.19
		iSVZ ≥ 40Gy ma	0.52 (0.26–1.03)	0.06
		cSVZ ≥ 30Gy vs < 30Gy	10.1 vs 6.9	0.025*	21.6 vs 21.2	0.29
		cSVZ ≥ 30Gy ma	0.45 (0.20–0.98)	0.04*
Khalifa 2017	43	SVZ without temporal horn:
		bSVZ > 40Gy vs ≤ 40Gy	9.4 vs 4.6	0.023*	22.7 vs 20.7	0.198
		V20Gy to bSVZ > 84% vs ≤84%	17.7 vs 5.2	0.017*	20.3 vs 22.7	0.19
		V20Gy to bSVZ ≤84% ma	2.67 (1.01–7.03)	0.047*

Abbreviations: iSVZ ipsilateral SVZ, bSVZ bilateral SVZ, cSVZ contralateral SVZ, VxGy volume of SVZ (%) receiving more than x Gy, TTP Time To progression, HR Hazard Ratio, OS Overall Survival, NC Not Known, NA Not Applicable, ma = multivariable analysis

*p <0.05